-
2025-523533-25-00
10
2026-03-26
Cancer-associated Cachexia
-
2023-503293-21-00
5
2026-03-25
Osteogenesis Imperfecta
-
2025-520467-40-00
9
2026-03-16
High-risk non-muscle invasive bladder cancer (NMIBC) with carcinoma in
-
2025-520805-10-00
5
2026-03-12
Chronic inflammatory demyelinating polyneuropathy (CIDP)
-
2025-522530-31-01
4
2026-02-27
Patients with metastatic PDAC, who have not progressed following compl
-
2025-522170-36-00
5
2026-02-03
Diabetes Mellitus, Type 1
-
2025-521797-34-00
5
2026-01-20
Diabetes Mellitus, Type 1
-
2024-520097-36-00
5
2026-01-07
Chronic inflammatory demyelinating polyneuropathy (CIDP)
-
2025-522052-13-00
10
2025-12-24
Framework for Optimizing, Refining, and Unifying Management of HSCT in
-
2025-521672-60-00
7
2025-12-19
Metastatic or locally advanced SST2-positive neuroendocrine neoplasms
-
2024-519901-36-00
5
2025-12-17
Patients with resected stage II-IIIA non-small cell lung cancer (NSCLC
-
2025-520982-39-00
5
2025-12-09
Philadelphia Chromosome Positive or ABL-class Philadelphia Chromosome-
-
2024-516906-47-00
10
2025-11-28
Locally Advanced or Metastatic Urothelial Carcinoma
-
2025-521707-48-00
1
2025-11-26
KRAS Altered Advanced or Metastatic Solid Tumors
-
2025-521775-31-00
5
2025-11-12
Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutations
-
2024-514879-17-00
5
2025-11-05
Gastric cancer
-
2024-514974-39-00
5
2025-10-10
Developmental and Epileptic Encephalopathies (DEEs)
-
2024-518645-17-00
5
2025-10-07
Blood and lymphatic diseases
-
2024-518589-29-00
5
2025-08-21
Bronchiectasis
-
2024-518973-32-00
5
2025-07-03
Chronic Graft-Versus-Host Disease
-
2023-509370-39-00
5
2025-06-03
connective tissue diseases
-
2024-515459-39-00
7
2025-05-08
Advanced or Metastatic Squamous Solid Tumors
-
2024-514459-14-00
4
2025-04-22
Non-Small Cell Lung Cancer
-
2024-514499-42-00
5
2025-03-12
Refractory Partial Onset Epilepsy